Tioga Medical, Inc.

Tioga Medical, Inc. is a US-based medical technology company specializing in innovative solutions for mitral valve replacement, focusing on advancing cardiac care through minimally invasive procedures. Tioga Medical, Inc. was founded in 2012 and is headquartered in Los Gatos, US.

The company develops transcatheter mitral valve replacement solutions, specifically the Tioga TMVR System. Mike Dineen, the founder, has a background in medical device innovation. Tioga Medical has raised a total of USD 16. 04 mn through funding, with its most recent Series C round completed on February 7, 2023, led by Cormorant Asset Management, alongside AMED Ventures and The Capital Partnership (U.

K. ) Limited, among others. Tioga Cardiovascular specializes in innovative solutions for mitral valve replacement, with its core offering being the Tioga TMVR System, designed for investigational use. This transcatheter device features a unique valve and anchor design that minimizes patient exclusions, effectively addressing mitral regurgitation (MR) in over 6.

6 million individuals in the U. S. The Tioga TMVR System utilizes a low-profile, 28 French delivery system with steerable catheters, enhancing procedural ease during deployment. The company targets healthcare providers, including cardiologists and hospitals in the US and Europe, focusing on the demand for less invasive cardiac procedures.

Tioga Cardiovascular's revenue model relies on partnerships with healthcare institutions that procure and utilize the Tioga TMVR System. The company anticipates revenue generation through the sales of this product following the completion of clinical trials and regulatory approvals. Pricing plans are tailored to the needs of medical facilities, with potential collaboration agreements and subscription models for ongoing support, aiming to enhance treatment outcomes for patients with MR. In February 2023, Tioga Medical, Inc.

raised USD 16. 04 mn in Series C funding to support the development of transseptal mitral valve replacement technologies and clinical testing of next-generation products. The company plans to introduce new offerings focused on mitral valve replacement and aims to expand into European markets by late 2024. The recent funding will facilitate these initiatives, enhancing their product lineup and market reach.